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The role of unnary kininogen in the regulation of kinin generation. The
kallikrein-kininogen-kinin system has been postulated to play a role in
the regulation of blood pressure and modulation of renal salt and water
transport. The activity of this system has usually been determined by
measurements of urinary kallikrein excretion. However, urinary kal-
likrein rarely correlates with simultaneously measured urinary kinins.
To further evaluate the factors influencing urinary kinin excretion, we
evaluated the role of urinary kininogen in this system. Urines were
analyzed from normal subjects and individuals with untreated essential
hypertension and end-stage renal disease. Intact urinary kininogen was
significantly correlated with urinary kinins in normal subjects (r = 0.65,P = 0.003) and essential hypertensives (r = 0.52, P = 0.026). In both
essential hypertension and end-stage renal disease, urinary kinins were
significantly decreased (8.00 1.93, 0.90 0.18, P < 0.05, respec-
tively) compared to controls (23.73 5.20). In essential hypertensives,
the reduction in urinary kinins was paralleled by a reduction in intact
kininogen with a normal excretion of kallikrein. In end-stage renal
disease, the reduction in kinins was paralleled by a reduction in
kallikrein with a normal excretion of intact kininogen. This data
suggests that kininogen may be an important determinant of urinary
kinin excretion in various disease states.
Le role du kininogene urinaire dans Ia regulation de Ia formation de
kinine. Un role du système kallicreine-kininogene-kinine a té envisage
dans la regulation de la pression artCrielle et Ia modulation des trans-
ports rénaux du sel et de l'eau. L'activité de ce système a habituetle-
ment été déterminëe par des mesures de l'excrCtion urinaire de kal-
licréine. Cependant, la kallicréine urinaire est rarement corrélèe avec
des mesures simultanées des kinines urinaires. Afin d'apprecier les
facteurs influencant l'excretion unnaire de kinine, nous avons etudie le
rOle du kininogene urinaire dans ce système. Les urines de sujets
normaux et de malades ayant une hypertension arterielle essentielle non
traitèe ou une insuffisance rCnale chronique terminale ont ete étudiées.
Le kininogene intact unnaire Ctait significativement corrClé avec les
kinines urinaires chez les sujets normaux (r = 0,65, p = 0,003) et chez
les hypertendus (r = 0,52, p = 0,026). Chez les malades hypertendus et
les insuffisants rénaux, les kinines urinaires Ctaient significativement
diminuees (8,00 1,93, 0,90 0,18, p < 0,05, respectivement)
comparees aux contrôles (23,73 5,20). Chez les hypertendus es-
sentiels, la reduction de Ia kinine urinaire etait accompagnée par une
reduction du kininogCne intact avec une excrCtion normale de kal-
licrèine. Au cours de l'insuffisance rCnale chronique, la reduction de la
kinine Ctait accompagnee d'une reduction de la kallicrèine avec une
excretion normale du kinogene intact. Ces resultats suggèrent que le
kininogène peut étre un determinant important de l'excrCtion urinaire
de kinine dans diffërents états pathologiques.
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The kinins have been implicated to have several important
physiologic functions, including the regulation of blood pres-
sure, salivary gland secretion, glucose uptake in muscle, mod-
ulation of salt and water transport in the kidney and intestines,
and enhancement of sperm motility [1—3]. Urine contains sev-
eral components of this vasoactive peptide system; kallikrein
[4], kinins [5—7], kininogen [6, 8—11], and kininases [12, 13].
Measurement of each of these components in urine may not
reflect the activity of this system at physiologically important
sites within the kidney. Indeed, the relative concentrations of
kallikrein, kininogen, and other possible modulating factors
such as pH and ions at intrarenal sites of kinin formation and
activity are not known [1, 2, 14, 15]. Thus, measurement of
relative concentrations in the urine after it is collected can lead
only to speculation of the intrarenal activity of the kallikrein-
kininogen-kinin system.
In several human diseases, alterations in urinary kallikrein
excretion have been reported [1, 2]. However, with rare excep-
tion, urinary kallikrein activity is not correlated with simulta-
neously measured urinary kinin excretion [1, 2, 16]. This lack of
correlation highlights the problems inherent in determining the
physiologic importance of urinary kinins from the measurement
of a single component of the system.
Very little information is available regarding the role of
urinary kininogen in the regulation of kinin formation.
Kininogen arising from glomerular ifitration of plasma
kininogen synthesized by the liver or from the secretion of
kininogen synthesized by the kidney [6, 101 has not been
considered to be an important modulator of renal kinin forma-
tion. However, this hypothesis has not been critically evaluated
and recent measurements of urinary kininogen suggests that
first-order kinetics apply. The Km for the reaction between
human urinary kallikrein and human low molecular weight
kininogen was reported to be 9.0 to 12.5 M [17, 18]. Human
urine contains intact low molecular weight kininogen, in a
concentration at least five-hundredfold below its Km for the
reaction with kallikrein [6, 9—11, 19]. Although urinary kinin
levels may not reflect the concentration at tissue sites, until
further information is available, such measurements may pro-
vide further insight into the physiologic importance of this
system.
To determine the possible physiological importance of
kininogen in the formation of kinin within the kidney, various
components of the renal kallikrein-kininogen-kinin system were
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measured in specific disease states. These disease states were
chosen because of expected alterations in either kallikrein or
kininogen. Individuals with untreated essential hypertension or
subjects with end-stage renal disease were compared to normal
subjects. The data suggest that urinary kininogen is a determi-
nant of urinary kinin formation. Furthermore, alterations in
urinary kininogen excretion may account for disease specific
abnormalities in kinin excretion.
Methods
All clinical investigations were carried out at the Roger
Williams General Hospital and Providence Veterans Adminis-
tration Medical Center. Human studies protocols were ap-
proved by the Institutional Review Boards of both hospitals,
and all patients gave informed consent. Three groups of patients
were studied. There were 21 normal volunteers (20 white and
one black) with an average age of 35.3 2.9 years. There were
16 men and five women. No subjects had hypertension or
evidence of renal, liver, cardiac, or thyroid disease. These
control subjects were allowed an ad lib sodium diet and 2 liters
of fluid daily. All medications, including over-the-counter prep-
arations, were discontinued for at least 1 week prior to study.
Twenty men with essential hypertension (19 white and one
black) with an average age of 56.3 1.5 years were studied.
The diagnosis of essential hypertension was established by
exclusion of secondary causes by history, physical examina-
tion, serum laboratory studies, urinalysis, urinary metaneph-
rines, and an intravenous pyelogram or renogram when indi-
cated. All subjects were studied on an ad lib diet with approx-
imately 2 liters of fluid intake daily. Anti-hypertensive medica-
tions were withdrawn 3 weeks prior to collection of the urine.
Eleven men with end-stage renal disease of various etiologies
(ten white and one black) with an average age of 56.3 2.9
years were studied. Six patients received outpatient
hemodialysis, while five were enrolled in an outpatient Contin-
uous Ambulatory Peritoneal Dialysis (CAPD) program. All
patients were instructed to restrict fluid intake to 1 to 2 liters
and sodium intake to 2 to 4 g daily. All medications were
withdrawn from these patients 24 hr prior to study.
A single 24-hr urine was collected from each subject as an
outpatient. Urinary creatinine excretion was measured to esti-
mate the completion of the 24-hr urine collection. Furthermore,
the method of collection was designed to minimize the loss of
kinins and kininogen without denaturing kallikrein [9, 20—22].
Subjects were encouraged to void as frequently as possible
throughout the day into a graduated beaker. Mter measuring
the volume of each void, one-half the urine was placed into a
bottle containing 9 ml of 6N HC1 and 1.5 mg of pepstatin, while
the other half of the urine was collected untreated. Urines were
stored at 4°C throughout the collection. Total volumes were
subsequently measured and aliquots stored at —70°C for later
analysis. We have found that collections obtained in this way
are stable for at least 18 months. Following the collection of
urine, blood was obtained after at least 4 hr of upright posture
for the measurements of plasma renin activity, serum electro-
lytes, and creatinine.
Since urinary kinins may not be an accurate reflection of
intrarenal kinins, subjects were encouraged to void as fre-
quently as possible during the studies to minimize kinin destruc-
tion by kininases and kinin formation by the action of uropepsin
and glandular kallikrein on urinary kininogen. The stability of
human urinary kinins while urine dwells within the bladder for
periods up to 1 hr was investigated previously (Weinberg MS,
unpublished data). Urine was collected through a Foley cathe-
ter directly into HC1-pepstatin in six normal female volunteers
during water diuresis. Following a 15-mm baseline collection,
the Foley catheter was clamped for 1 hr and then released. A
second 15-mm collection of free-flowing urine was obtained
alter the 1-hr period during which time urine was left in the
bladder. Urinary kinin levels in the sample dwelling in the
bladder for 1 hr were decreased 10.2 6.8% compared to the
mean of the two urines obtained during free flow. Since the
stability of urinary kinins while urine dwells in the bladder for
more than 1 hr was not evaluated, subjects were asked to void
at intervals no greater than 1 hr. In addition, acid pH (5 to 6)
suppressed while basic pH (6 to 8) enhanced kininase activity.
We, therefore, felt justified in allowing urine to dwell in the
bladder overnight because urine is usually acidic alter an
overnight fast.
Assays
Urinary kallikrein radioimmunoassay
Purified human urinary kallikrein and rabbit anti-human
urinary kallikrein serum was generously supplied by Dr.
Narendra B. Oza, Boston, Massachusetts, USA. The radio-
immunoassay procedure, measuring total (active and inactive)
kallikrein, has been described previously [23] and was modified
by the addition of 25 Mi ofgoat-anti-rabbit antibody on insoluble
matrix following the incubation period. After 15 mm of equili-
bration, the bound radioactivity was removed by centrifugation
at 4000 rpm for 15 mm in a refrigerated centrifuge. The pellet
was then counted using a Hewlett-Packard 9815S system with
log/logit plots. The non-specific binding, obtained by replacing
anti-kallikrein serum with normal rabbit serum, ranged from 2
to 4% and was subtracted from each reaction. Urine samples
and purified kallikrein for the standard curve were assayed in
triplicate. The inter-assay coefficient of variation of a human
urine pool was 11%. The intra-assay coefficient of variation was
6.1%. The recovery of purified human urinary kallikrein was
120 15%.
Urinary kinin radioimmunoassay
Determination of kinins in urine was performed by radio-
immunoassay using a highly specific rabbit antibradykinin se-
rum generously supplied by Dr. Cohn Johnston (Melbourne,
Australia) as reported previously [22, 24]. Non-specific binding
determined by substituting normal rabbit serum for the
antibradykinin serum ranged from 2.5 to 4.0% and was sub-
tracted from all experimental data. The standard curve ranged
from 25 to 1000 pg of bradykinin. In eight experiments, the total
binding was 28.4 2.5% and the B/Bo values produced by
addition of 50, 250, and 750 pg of unlabeled bradykinin were
82.1 3.0, 57.8 3.0, and 33.1 3.0%, respectively. An
internal standard consisting of a normal human urine pool
collected in HC1-pepstatin was used in each kinin assay. The
inter-assay coefficient of variation of the human urinary kinin
pooi was 10.4%. The intra-assay coefficient of variation of this
pool was 6.5%. The recovery of synthetic bradykinin added to
the human urine pooi was 96.3 4.3%. The cross reactivity
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between bradykinin antiserum and purified human low molec-
ular weight kininogen, generously supplied by Drs. Jack Pierce
and John Pisano (Bethesda, Maryland, USA), was 3%.
Determination of kininogen excretion
Total urinary kininogen was calculated by measuring the total
amount of kinins generated in urine following trypsinization.
Preformed urinary kinin levels were determined in the absence
of trypsin. Intact kininogen in each sample was calculated from
the difference between total kinins generated after trypsiniza-
tion and preformed kinins. The incubation with trypsin was
performed as described previously [221. Both total and intact
kininogen were reported in jsg of kinins/day. Quantitative
estimates of the urinary excretion of kininogen were made by
assuming that 11.2 j.g of kinins are generated from the complete
degradation of 1 mg of human low molecular weight kininogen
[25]. These calculations were performed to compare excretory
levels to the known Km between human urinary kallikrein and
low molecular weight kininogen. The method of determining
kininogen by measuring kinins generated following trypsiniza-
tion agrees well with levels of urinary kininogen reported by
others using direct radioimmunoassay with an antikininogen
antibody [10, 19].
Other analyses
Plasma renin activity was determined using the GammaCoat
plasma renin activity radioimmunoassay kit (Clinical Assays,
Cambridge, Massachusetts, USA). Urinary aldosterone excre-
tion was measured by radioimmunoassay using the Coat-A-
Count solid phase radioimmunoassay kit (Diagnostic Products,
Los Angeles, California, USA). The inter-assay variabilities of
plasma renin activity and urinary aldosterone were 4.9% and
6.2%, respectively. Serum creatinine was determined by rou-
tine analysis. Urinary sodium and potassium were measured by
flame photometry using lithium as an internal standard.
Statistics
Differences between normal controls and subjects with es-
sential hypertension and end-stage renal disease were tested
using multiple analysis of variance (MANOVA) or multiple
analysis of covariance (MANCOVA) since multiple dependent
measures were used with a nominal-level factor [26]. Since
differences in subject age and urinary sodium rather than group
conditions might be responsible for observed differences in
group means, MANCOVA was performed controlling for uri-
nary sodium and age for urinary kallikrein [1, 27], and plasma
renin activity and urinary aldosterone [281, while age alone was
covaried for systolic and diastolic blood pressure [29]. In every
case, the effect of the covariate was equivalent within each of
the groups [30]. No covariates were used for urinary total and
intact kininogen and kinins since no data is available relating
their excretion with either age or urinary sodium. We, indeed,
found no significant correlations using Pearson correlation test
between either age or urinary sodium excretion and kininogen
or kinins in any of our study groups. In addition, no correlations
were found between age and urinary sodium and urinary
kininogen or kinins when either urinary sodium or age were
used as covariates.
After multivariate analysis established a significant overall
effect between the groups, the use of univariate analysis,
Table 1. Correlations between urinary kinin excretion and parameters
studied in normal subjects
Urinary kinin excretion
ra p
Systolic blood pressure, mm Hg 0.222 NS
Diastolic blood pressure, mm Hg —0.200 NS
Urinary flow, liters/day —0.020 NS
Urinary potassium, mEq/day 0.063 NS
Urinary aldosterone, sg/day 0.266 NS
Kallikrein, /.Lg/day 0.071 NS
Intact kininogen, g kinin/day 0.645 .003
a Partial correlation coefficients with age
covariates.
b Significance values, NS is F> 0.05.
and urinary sodium as
ANCOVA and ANOVA, then located statistically significant
main effects for the group factor with all of the dependent
variables [26]. Statistical tests were performed on means
adjusted for the effect of covariates when covariates were used.
Significantly different group means for those variables with a
main effect for the group were determined by the Dunnett
specialized multiple-comparison test [31].
Partial correlations with age and urinary sodium as covariates
were performed within each group between the dependent
variables [32].
Results
Control subjects
In normal volunteers, kallikrein, kinin, and kininogen levels
were not different between males and females, and, therefore,
the data were pooled. The excretion of total and intact kininogen
was 36.69 6.9 and 12.96 2.4 g of kinins/day, respectively.
Assuming 1 mg of human low molecular weight kininogen can
generate 11.2 g/ml of kinins [25], the urinary levels of total and
intact kininogen were calculated to be 2.6 0.6 g
kininogen/ml and 0.9 0.2 g kininogenlml, respectively. In
view of the reported Km for the reaction between kallikrein and
kininogen of 9—12.5 ELM, or 0.6 to 1.0 mg/ml assuming the
molecular weight of low molecular weight kininogen is approx-
imately 68,000 daltons [25], the urinary levels of intact
kininogen in normals are approximately 1000 times less than its
Km. This assumes normal human urine contains low but not
high molecular weight kininogen (MUller-Esterl, Werner, and
Weinberg MS, unpublished observations).
Table 1 contains partial correlations controlling for age and
urinary sodium for all variables studied in normal volunteers.
Urinary kinins were significantly correlated with intact
kininogen. No correlation was noted between urinary kinin
excretion and kallikrein excretion.
In Table 2, the observed means and statistically significant
group differences are shown for normals and subjects with
essential hypertension and end-stage renal disease. Hyperten-
sives were significantly older and had greater urine flow than
controls, but had no differences in plasma renin activity and
creatinine, or urinary potassium, sodium, and aldosterone.
Diastolic blood pressure was significantly elevated, while sys-
tolic blood pressure was arithmetically, but not significantly,
increased. Subjects with end-stage renal disease were also older
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Table 2. Group characteristics in normals, essential hypertensives, and end-stage renal disease subjects
Normal
(N=21) Hypertensive(N=20)
Renal disease
(N=11)
Age, years 35.3 2.9 56.3 1.5 56.6 3.l
Systolic blood pressure, mm Hg 127 5 146 5 140 6
Diastolic blood pressure, mm Hg 78 4 97 3a 66 4
Plasma
Renin, ng/ml/min 2.41 0.53 2.25 0.48 2.76 0.71
Creatinine, mg% 0.78 0.04 0.90 0.30 12.98 l.34a
Urinary
Flow, liters/day 1.27 0.15 1.76 0.14a 0.55 0.l9
Aldosterone, jsg/day 7.14 1.55 9.88 1.40 3.81 2.08
Potassium, mEq/day 50.0 7.3 65.8 9,8 25.1 5.1
Sodium, mEqiday 99.3 13.2 118.4 12.6 36.7 6.8a
Creatinine, g/day 1.53 0.09 1.60 0.08 0.63 0.19
Data are mean SE.
a P < 0.05 compared to Normal group.
subjects
Normal
(N 21)
Hypertensive
(N = 20)
Renal d
(N =
isease
11)
Total kininogen,
jsg kinin/day 36.69 6.99 11.34 2.42a 22.75 9.90
Intact kininogen,
sg kinin/day 12.96 2.40 3.34 0.76a 21.85 9.90
Kinins, pgIday 23.73 5.20 8.00 1.93a 0.90 0.18
Kallikrein,
j.g/day 116.56 29.58 175.59 26.70 11.84 39.70a
than controls, had significantly elevated plasma creatinine
levels, and significantly decreased urinary flow, sodium excre-
tion, and diastolic blood pressure. There were no differences in
plasma renin activity or urinary potassium and aldosterone
excretion. Systolic blood pressure was arithmetically, but not
significantly, increased.
Components of the urinary kallikrein-kininogen-kinin system
are shown in Table 3 and Figure 1. Compared to normal
subjects, patients with hypertension and end-stage renal disease
had significantly reduced urinary kinin excretion. Total and
intact kininogen were decreased in hypertensives but not end-
stage renal disease patients, while kallikrein was significantly
decreased in end-stage renal disease but not hypertension.
Correlations among components of the kallikrein-kininogen-
kinin system
To gain insight into the relationship between components of
the kallikrein-kininogen-kinin system and other parameters
studied, as well as to compare our study population to previous
investigations, partial correlations controlling for age and uri-
nary sodium were performed for all variables in the three
groups. In normal volunteers, preformed kinins were signifi-
cantly correlated to intact kininogen, as can be seen in Table 1.
Furthermore, intact kininogen was correlated to kallikrein (r =
0.52, P = 0.025) and urinary aldosterone (r = 0.57, P = 0.011),
while kallikrein and aldosterone were also related (r = 0.52, P
Normals HTN ESRD(N = 21) (N = 20) (N = 11)
Fig. 1. Components of the kallikrein-kininogen-kinin system in normals,
essential hypertensives (HTN), and end-stage renal disease (ESRD)
subjects. N is number of subjects in each group. Bars represent the
24-hr urinary excretion of total kininogen (n), intact kininogen (),
kallikrein (.), and kinin (). *D < 0.05.
0.024). Furthermore, intact kininogen was significantly cor-
related (r = 0.41, P = 0.045) to aldosterone even when
kallikrein, age, and urinary sodium were used as covariates. In
hypertensives, urinary kinins were correlated to intact
kininogen (r = 0.52, P = 0.026) (similar to the findings in control
subjects). Kallikrein excretion was significantly correlated to
aldosterone (r = 0.65, P = 0.004) and urinary potassium (r =
0.69, P = 0.001), while intact kininogen and urine flow (r =
0.50, P = 0.036), and aldosterone and urinary potassium (r =
0.67, P = 0.003) were related. In end-stage renal disease,
diastolic blood pressure was correlated to total kininogen (r =
— 0.72, P = 0.014), intact kininogen (r = — 0.73, P = 0.013),
and aldosterone (r = 0.68, P = 0.022). Aldosterone was
Table 3. Components of the urinary kallikrein-kininogen-kinin system
in normals, essential hypertensives, and end-stage renal disease 40
30
20
10
Data are mean SE.
a P < 0.05 compared to Normal group. 50
100
150
'I-
200
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correlated to total kininogen (r =
—0.58, P = 0.05) and intact
kininogen (r = —0.59, P = 0.47), while urine flow was corre-
lated to kallikrein (r = 0.66, P = 0.026).
Discussion
Kinins are potent vasoactive peptides. Their ability to pro-
duce vasorelaxation has resulted in speculation about a role for
kinins in the physiologic regulation of blood pressure and renal
sodium excretion [1, 2]. Specific kinin receptors have been
identified in vascular endothelial cells as well as in the distal
tubular cell of the kidney [33]. Kinins might influence physio-
logic processes in these tissues by means of a change in the
concentration of kinins at the receptor site (determined by the
balance between kinin formation and degradation) and/or an
alteration in kinin receptor number or affinity. In addition, any
factors that affect the intracellular events that follow the kinin-
receptor interaction might also determine the physiologic im-
portance of kinins.
To date, most studies of the physiologic role of renal kinins
have focused upon the concentration of kinins in urine and/or
urinary kallikrein, which catalyzes the release of active kinins
from inactive substrate, kininogen. It is important to note,
however, that most studies have failed to find any correlation
between urinary excretion of kallikrein and kinins. While this
lack of correlation in urine may not reflect activities at tissue
sites, it is consistent with the hypothesis that other factors are
important in the regulation of kinin formation in urine.
Three major findings of this study support the hypothesis that
urinary kininogen is a physiologically important determinant of
urinary kinin excretion. First, using a highly specific antibody
to bradykinin and a method for collecting urine designed to
kininogen argues for the utility of this method [10, 19].
A second finding was the highly significant correlations
between the excretion of urinary intact kininogen and urinary
kinins. This positive correlation was found in both normal
subjects and in those with hypertension. Furthermore, in both
these groups, there was no correlation between urinary kal-
likrein and urinary kinins. This observation is consistent with
excretion is seen in hypertensives and patients with end-stage
renal disease. In hypertensives, the kinin deficiency is associ-
ated with a deficiency of urinary kininogen excretion with
normal excretion of kallikrein. In contrast, in patients with
end-stage renal disease, kinin excretion is depressed in associ-
ation with a decrease in urinary kallikrein excretion while
kininogen excretion is normal. The use of covariate analysis
indicates that the alterations in kininogen excretion between the
three groups cannot be attributed to differences in age, systolic
pressure, urinary excretion of sodium, potassium, or aldosterone, or
plasma renin activity. Thus, these two pathophysiologic conditions
support the hypothesis that urinary kininogen excretion might be
important in the regulation of urinary kinin excretion. The physio-
logic importance of this hypothesis might be tested by altering
kininogen excretion through experimental maneuvers.
Previous studies in hypertensives have focused upon urinary
kallikrein excretion. A deficiency of either total kallikrein
excretion [21, 37, 38] or kallikrein activity [37, 39—49) or the
ratio of active to total kallikrein [24] has been reported by some
but not all studies [24, 27, 50—57]. Kinin secretion was found to
be depressed by Shimamoto [21], but no studies have reported
simultaneously on all three components of this system in
hypertensive patients.
In our hypertensive patient population, total kallikrein excre-
tion was similar to our control group. Nevertheless, a marked
reduction in kinin excretion was found (23.7 vs. 8.0 pg/day)
compared to the normal group. We do not believe that these
differences can be explained by group differences in age,
sodium or potassium excretion, urinary aldosterone, plasma
renin activity, or systolic blood pressure. The reduced excre-
tion of kinins might be the result of either increased degradation
or decreased formation. A marked reduction in urinary
kininogen excretion in these patients was found. While we
cannot exclude changes in kallikrein activity as a contributor to
the reduced kinins in urine, measurements of total kallikrein by
radioimmunoassay have been found to correlate significantly
with active kallikrein in both normals and hypertensives [37,
50]. In view of the kinetics of the kallikrein-kininogen-kinin
interaction, it is attractive to attribute the decrease in kinin
excretion to the deficiency of kininogen excretion and therefore
decreased kinin formation.
A deficiency of kinin excretion was also noted in subjects
with end-stage renal disease, and this was found in the presence
of a markedly depressed urinary total kallikrein excretion.
Although decreases in urinary kallikrein excretion have been
noted in some studies of end-stage renal disease [53, 58],
elevated [59—61], and normal levels [62, 63] of kallikrein activity
have also been reported. Since our assay measures total kal-
be found in our patients. The reason for the different kallikrein
excretions in subjects with renal disease reported by other
investigators may relate to differences in severity of disease,
study population, and methodology. Although reduction in
kinin excretion might result from an increase in degradation in
the urine, it is again attractive to speculate that a reduction in
formation of kinins resulting from a deficiency of kallikrein
minimize kinin degradation, we determined urinary excretion of
kinins to be 23.7 5.2 tg/day. These values compare favorably
to the range of 8 to 42.3 igIday reported by others [5—7, 9, 10,
21, 34-36]. Utilizing this sensitive assay and a standard tech-
nique for releasing kinins from kininogen, we were then able to
calculate kininogen excretion. Intact kininogen levels were
approximately 0.91 g/ml (0 to 3.3 pg/mi range), almost one-
thousandfold less than the Km for the reaction between urinary
kallikrein and urinary kininogen. These are the precise condi-
tions in which substrate concentrations become a significant
determinant of product formation. Our calculation of total
urinary kininogen is based upon total kinins generated after
trypsinization and therefore detects functionally intact
kininogen as well as endogenous kinins already released from
des-kinin-kininogen. While these calculations may be affected
by destruction of kinins at sites proximal to the bladder, the fact
that these calculated values for total kininogen compare remark-
ably well with the values reported using bispecific antibodies to total likrein protein, it is likely that a reduction in activity would also
the hypothesis that urinary kininogen is a physiologic regulator played the major role.
of urinary kinin excretion. The precise role of urinary kininogen in the physiologic
The third major finding and the one of greatest physiologic regulation of the renal kallikrein-kininogen-kinin system re-
interest is the observation that a deficiency in urinary kinin mains speculative. The data presented suggest that urinary
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kininogen may be an important regulator of kinin excretion.
Furthermore, in certain disease conditions, kininogen defi-
ciency may be of pathophysiologic significance.
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